HMGB2 and malaria: That is why our report on long-lasting cross protection determined by murine infection of a genetically attenuated parasite lacking HMGB2 protein might be the first step to propose a novel strategy for malaria vaccination leading to a clinical study of hmgb2 inactivated P. falciparum).